Back to VICL Stock Lookup
Pages: 1 2 3 »» Last Page

Vical (VICL) – Press Releases

Aug 30, 2019 11:54 AM Vical Stockholders Approve Reverse Stock Split and Merger with Brickell
Aug 1, 2019 04:10 PM Hercules Capital Reports Second Quarter 2019 Financial Results
Jun 25, 2019 06:00 AM Hercules Capital Announces Multiple Portfolio Company Achievements in Q2 2019
Jun 3, 2019 03:00 AM Vical and Brickell Announce Merger Agreement
Feb 19, 2019 05:45 PM Vical to Discontinue Clinical Development of VL-2397 as it Considers Near Term Strategic Alternatives
Nov 1, 2018 08:15 AM New Research: Key Drivers of Growth for Interface, USA Truck, Weingarten Realty Investors, Unum Group, Trivago N.V. ADS, and Vical — Factors of Influence, Major Initiatives and Sustained Production
Oct 29, 2018 06:30 AM Vical Reports Third Quarter 2018 Financial and Operational Results
Aug 23, 2018 08:00 AM Vical to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
Aug 7, 2018 06:30 AM Vical Reports Second Quarter 2018 Financial and Operational Results
Jul 19, 2018 06:00 AM Vical Announces Review of Potential Strategic Transactions
Jun 11, 2018 06:00 AM Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
May 3, 2018 06:30 AM Vical Reports First Quarter 2018 Financial and Operational Results
Apr 26, 2018 04:05 PM Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results
Mar 15, 2018 06:30 AM Vical Reports Fourth Quarter 2017 Financial and Operational Results
Mar 8, 2018 09:07 PM Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
Mar 8, 2018 04:05 PM Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results
Feb 20, 2018 06:00 AM Vical Initiates Phase 2 Trial of VL-2397 Antifungal for Invasive Aspergillosis
Feb 1, 2018 06:30 AM Vical and Mycoses Study Group Education and Research Consortium Establish Collaboration to Advance Vical’s Novel Antifungal VL-2397 for the Treatment of Invasive Aspergillosis
Jan 30, 2018 04:15 PM Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
Jan 29, 2018 10:17 AM Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
Jan 22, 2018 03:00 AM Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Jan 22, 2018 03:00 AM Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
Nov 8, 2017 06:30 AM Vical Incorporated Announces Pricing of $25 Million Underwritten Public Offering of Common Stock
Oct 24, 2017 06:30 AM Vical Announces Joint Development Program With AnGes on a Treatment for Chronic Hepatitis B Infection
Oct 23, 2017 06:30 AM Vical Reports Third Quarter 2017 Financial and Operational Results
Oct 16, 2017 05:30 PM Vical Announces News Release and Conference Call Schedule for Third Quarter 2017 Financial Results
Oct 13, 2017 04:05 PM Vical to Provide Company Update at BIO Investor Forum Conference
Oct 10, 2017 06:30 AM Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial
Oct 2, 2017 04:15 PM Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA Based on a Single Phase 2 Efficacy Trial
Sep 28, 2017 06:00 AM Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
Sep 6, 2017 03:00 PM Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
Aug 8, 2017 06:30 AM Vical Reports Second Quarter 2017 Financial and Operational Results
Aug 1, 2017 04:05 PM Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results
Jun 15, 2017 04:05 PM Vical to Provide Company Update at the 2017 BIO International Convention
Jun 5, 2017 06:30 AM Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
May 23, 2017 06:30 AM Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
May 15, 2017 06:30 AM Vical Reports First Quarter 2017 Financial Results
May 8, 2017 06:30 AM Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
May 2, 2017 04:36 PM Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
Apr 24, 2017 06:30 AM Vical to Host Virtual Research & Development Day on May 2, 2017
Apr 19, 2017 06:30 AM Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
Mar 10, 2017 06:30 AM Vical to Provide Company Update at the 29th Annual ROTH Conference
Mar 9, 2017 07:00 AM Vical to Provide Company Update at BIO Asia International Conference
Mar 9, 2017 06:30 AM Vical Reports Fourth Quarter 2016 Financial Results
Mar 2, 2017 06:30 AM Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results
Feb 24, 2017 03:00 PM Vical Provides Company Update at Biocom's Global Life Science Partnering Conference
Feb 7, 2017 06:30 AM Vical Provides Company Update at BIO CEO and Investor Conference
Nov 3, 2016 06:30 AM Vical Reports Third Quarter 2016 Financial Results
Oct 27, 2016 06:30 AM Vical Announces News Release and Conference Call Schedule for Third Quarter 2016 Financial Results
Sep 26, 2016 06:30 AM Vical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes
Pages: 1 2 3 »» Last Page

Back to VICL Stock Lookup